Does empagliflozin reduce the incidence of CTRCD in high-risk patients treated with anthracyclines?
Empagliflozin may reduce the incidence of cancer therapeutics-related cardiac dysfunction in high-risk patients receiving anthracyclines, supporting the need for larger clinical trials.
Empagliflozin is associated with reduced incidence of CTRCD in high-risk patients treated with anthracyclines. These data should serve as the foundation for a clinical trial to test whether SGLT2 inhibitors can reduce the incidence of heart failure in this patient group.
Daniele et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: